Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia

Sabrina Ravaglia, Paola Bini, Elena Sinforiani, Diego Franciotta, Elisabetta Zardini, Pietro Tosca, Arrigo Moglia, Alfredo Costa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In 31 patients with probable Alzheimer's disease (AD), 19 with probable vascular dementia (VaD) and 20 with Possible AD and Possible VaD, cerebrospinal fluid (CSF) tau levels hyperphosphorylated at threonine 181 (Ptau) were measured by ELISA. Thirty-six age-matched subjects were used as controls. The severity of the cognitive decline was assessed at the time of CSF analysis and after a 12-month follow-up. The groups had comparable age, degree of cognitive impairment and disease duration; these parameters were not related to P-tau levels. P-tau discriminated between demented patients and controls, but no significant difference emerged between AD and the other groups. By contrast, higher P-tau values were found to predict, independently of the clinical diagnosis, a more rapid evolution of cognitive decline. Whether these findings are due to a lack of CSF P-tau specificity or to the low reliability of clinical and radiological criteria remains unclear. P-tau may be useful in the evaluation of disease evolution, by predicting the rate of cognitive decline.

Original languageEnglish
Pages (from-to)417-423
Number of pages7
JournalNeurological Sciences
Volume29
Issue number6
DOIs
Publication statusPublished - 2008

Fingerprint

Vascular Dementia
Threonine
Cerebrospinal Fluid
Alzheimer Disease
Enzyme-Linked Immunosorbent Assay
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • Biological markers
  • Cerebrospinal fluid
  • Tau protein
  • Vascular dementia

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. / Ravaglia, Sabrina; Bini, Paola; Sinforiani, Elena; Franciotta, Diego; Zardini, Elisabetta; Tosca, Pietro; Moglia, Arrigo; Costa, Alfredo.

In: Neurological Sciences, Vol. 29, No. 6, 2008, p. 417-423.

Research output: Contribution to journalArticle

@article{63cb343936f94dfd8f85eda588ddf895,
title = "Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia",
abstract = "In 31 patients with probable Alzheimer's disease (AD), 19 with probable vascular dementia (VaD) and 20 with Possible AD and Possible VaD, cerebrospinal fluid (CSF) tau levels hyperphosphorylated at threonine 181 (Ptau) were measured by ELISA. Thirty-six age-matched subjects were used as controls. The severity of the cognitive decline was assessed at the time of CSF analysis and after a 12-month follow-up. The groups had comparable age, degree of cognitive impairment and disease duration; these parameters were not related to P-tau levels. P-tau discriminated between demented patients and controls, but no significant difference emerged between AD and the other groups. By contrast, higher P-tau values were found to predict, independently of the clinical diagnosis, a more rapid evolution of cognitive decline. Whether these findings are due to a lack of CSF P-tau specificity or to the low reliability of clinical and radiological criteria remains unclear. P-tau may be useful in the evaluation of disease evolution, by predicting the rate of cognitive decline.",
keywords = "Alzheimer's disease, Biological markers, Cerebrospinal fluid, Tau protein, Vascular dementia",
author = "Sabrina Ravaglia and Paola Bini and Elena Sinforiani and Diego Franciotta and Elisabetta Zardini and Pietro Tosca and Arrigo Moglia and Alfredo Costa",
year = "2008",
doi = "10.1007/s10072-008-1023-1",
language = "English",
volume = "29",
pages = "417--423",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "6",

}

TY - JOUR

T1 - Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia

AU - Ravaglia, Sabrina

AU - Bini, Paola

AU - Sinforiani, Elena

AU - Franciotta, Diego

AU - Zardini, Elisabetta

AU - Tosca, Pietro

AU - Moglia, Arrigo

AU - Costa, Alfredo

PY - 2008

Y1 - 2008

N2 - In 31 patients with probable Alzheimer's disease (AD), 19 with probable vascular dementia (VaD) and 20 with Possible AD and Possible VaD, cerebrospinal fluid (CSF) tau levels hyperphosphorylated at threonine 181 (Ptau) were measured by ELISA. Thirty-six age-matched subjects were used as controls. The severity of the cognitive decline was assessed at the time of CSF analysis and after a 12-month follow-up. The groups had comparable age, degree of cognitive impairment and disease duration; these parameters were not related to P-tau levels. P-tau discriminated between demented patients and controls, but no significant difference emerged between AD and the other groups. By contrast, higher P-tau values were found to predict, independently of the clinical diagnosis, a more rapid evolution of cognitive decline. Whether these findings are due to a lack of CSF P-tau specificity or to the low reliability of clinical and radiological criteria remains unclear. P-tau may be useful in the evaluation of disease evolution, by predicting the rate of cognitive decline.

AB - In 31 patients with probable Alzheimer's disease (AD), 19 with probable vascular dementia (VaD) and 20 with Possible AD and Possible VaD, cerebrospinal fluid (CSF) tau levels hyperphosphorylated at threonine 181 (Ptau) were measured by ELISA. Thirty-six age-matched subjects were used as controls. The severity of the cognitive decline was assessed at the time of CSF analysis and after a 12-month follow-up. The groups had comparable age, degree of cognitive impairment and disease duration; these parameters were not related to P-tau levels. P-tau discriminated between demented patients and controls, but no significant difference emerged between AD and the other groups. By contrast, higher P-tau values were found to predict, independently of the clinical diagnosis, a more rapid evolution of cognitive decline. Whether these findings are due to a lack of CSF P-tau specificity or to the low reliability of clinical and radiological criteria remains unclear. P-tau may be useful in the evaluation of disease evolution, by predicting the rate of cognitive decline.

KW - Alzheimer's disease

KW - Biological markers

KW - Cerebrospinal fluid

KW - Tau protein

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=58149085383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149085383&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-1023-1

DO - 10.1007/s10072-008-1023-1

M3 - Article

VL - 29

SP - 417

EP - 423

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 6

ER -